Perrigo Co. (PRGO)
-NasdaqGS 118.61 
0.08(0.07%) 4:00PM EDT|After Hours
:
118.61 0.01 (0.01%) 4:13PM EDT - Nasdaq Real Time Price
| Prev Close: | 118.53 |
|---|
| Open: | 118.77 |
|---|
| Bid: | 117.48 x 100 |
|---|
| Ask: | 119.38 x 100 |
|---|
| 1y Target Est: | 124.80 |
|---|
| Beta: | 0.2 |
|---|
| Next Earnings Date: | 7-May-13 |
|---|
| Day's Range: | 118.05 - 119.49 |
|---|
| 52wk Range: | 96.52 - 121.12 |
|---|
| Volume: | 244,194 |
|---|
| Avg Vol (3m): | 569,093 |
|---|
| Market Cap: | 11.15B |
|---|
| P/E (ttm): | 25.23 |
|---|
| EPS (ttm): | 4.70 |
|---|
| Div & Yield: | 0.36 (0.30%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Daily Dividend Report: HAR, STX, STJ, PRGO, RDSat Forbes(Thu 12:47PM EDT)
- Key for Big Generic Players is Focusing on Higher Value Opportunities that Provide Sustainable Cash Flows: Expert Analyst David Amsellem Discusses the Pharmaceutical Sector with The Wall Street TranscriptWall Street Transcript(Thu 11:31AM EDT)
- Perrigo Company Announces Quarterly DividendPR Newswire(Thu 8:40AM EDT)
- 3 Healthcare Picks From Janus Fundat Motley Fool(Wed, May 1)
- Scared of a Market Fall? Watch These Defensive Growth Stocksat Motley Fool(Tue, Apr 30)
- AbbVie Q1: Story of Humira and the 7 Dwarfsat Motley Fool(Sat, Apr 27)
- Covidien's 2Q Earnings BeatZacks(Fri, Apr 26)
- Stryker's 1Q Earnings Beat Est.; Sales LagZacks(Thu, Apr 25)
- How Will AbbVie's Earnings Fare?at Motley Fool(Wed, Apr 24)
- Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013PR Newswire(Tue, Apr 23)
- Is Perrigo a Stealth Superstar?at Wall St. Cheat Sheet(Mon, Apr 22)
- Covidien Collaborates with VIDAZacks(Wed, Apr 17)
- My Thoughts On Taroat Seeking Alpha(Sun, Apr 14)
- Landmark Judgment Could Give These Stocks a Boostat Motley Fool(Fri, Apr 12)
- Valeant EPS Outlook Hit By Surprise Generic Approvalat Investor's Business Daily(Thu, Apr 4)
Key Statistics
| Forward P/E (1 yr): | 17.97 |
|---|
| P/S (ttm): | 3.41 |
|---|
| Ex-Dividend Date: | 27-Feb-13 |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | 5.66 |
|---|
| Quarterly EPS Est
(Mar-13)
: | 1.44 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 1.78 |
|---|
Business Summary
Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide.
View More